Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma

Descripción del Articulo

Renal cell carcinoma (RCC) is a heterogenous disease which the incidence is increasing worldwide. The identification and understanding of the role of the Von Hipple Lindau (VHP) in regulating the hypoxia-inducible factor signaling pathway has revolutionized the treatment of this disease. Belzutifan...

Descripción completa

Detalles Bibliográficos
Autores: Rioja, Patricia, Rey-Cardenas, M, De Velasco, Guillermo
Formato: artículo
Fecha de Publicación:2025
Institución:Instituto Nacional de Enfermedades Neoplásicas
Repositorio:INEN-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.inen.sld.pe:20.500.14703/475
Enlace del recurso:https://doi.org/10.1016/j.ctrv.2024.102801
https://hdl.handle.net/20.500.14703/475
Nivel de acceso:acceso abierto
Materia:anemia
cell carcinoma
https://purl.org/pe-repo/ocde/ford#3.02.30
id INEN_c7d27c1e77d4d0773df0a516c40399f1
oai_identifier_str oai:repositorio.inen.sld.pe:20.500.14703/475
network_acronym_str INEN
network_name_str INEN-Institucional
repository_id_str .
dc.title.none.fl_str_mv Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
title Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
spellingShingle Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
Rioja, Patricia
anemia
cell carcinoma
https://purl.org/pe-repo/ocde/ford#3.02.30
title_short Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
title_full Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
title_fullStr Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
title_full_unstemmed Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
title_sort Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
author Rioja, Patricia
author_facet Rioja, Patricia
Rey-Cardenas, M
De Velasco, Guillermo
author_role author
author2 Rey-Cardenas, M
De Velasco, Guillermo
author2_role author
author
dc.contributor.author.fl_str_mv Rioja, Patricia
Rey-Cardenas, M
De Velasco, Guillermo
dc.subject.none.fl_str_mv anemia
cell carcinoma
topic anemia
cell carcinoma
https://purl.org/pe-repo/ocde/ford#3.02.30
dc.subject.ocde.none.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.02.30
description Renal cell carcinoma (RCC) is a heterogenous disease which the incidence is increasing worldwide. The identification and understanding of the role of the Von Hipple Lindau (VHP) in regulating the hypoxia-inducible factor signaling pathway has revolutionized the treatment of this disease. Belzutifan is an oral hypoxiainducible factor (HIF)-2α inhibitor, which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease and for the treatment of adults with RCC who experienced disease progression after PD-1/PD-L1– and VEGFR-targeted therapies. One of the most common adverse effect of this drug is anemia; however, it is treatment is not well known. This review summarizes role of the VHL-HIF pathway in ccRCC aroused the interest of targeting HIF activity, the history of belzutifan development and their relationship to anemia as well as propose a management algorithm
publishDate 2025
dc.date.accessioned.none.fl_str_mv 2025-09-30T08:29:10Z
dc.date.available.none.fl_str_mv 2025-09-30T08:29:10Z
dc.date.issued.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.ctrv.2024.102801
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.14703/475
dc.identifier.journal.none.fl_str_mv Cancer Treatment Reviews
url https://doi.org/10.1016/j.ctrv.2024.102801
https://hdl.handle.net/20.500.14703/475
identifier_str_mv Cancer Treatment Reviews
dc.language.iso.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
dc.publisher.country.none.fl_str_mv UK
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:INEN-Institucional
instname:Instituto Nacional de Enfermedades Neoplásicas
instacron:INEN
instname_str Instituto Nacional de Enfermedades Neoplásicas
instacron_str INEN
institution INEN
reponame_str INEN-Institucional
collection INEN-Institucional
bitstream.url.fl_str_mv https://repositorio.inen.sld.pe/backend/api/core/bitstreams/5ccdd6de-0ac5-436b-bfdd-1257dc78e484/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/9c6dad5a-e942-40c2-ab83-21c4a9e0be42/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/b6e2e749-1a7d-4f0f-8fee-e9a907a5d2d3/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/e87620ff-8001-40c1-ae48-7d63485a84be/download
bitstream.checksum.fl_str_mv 6c94a0f53e92fb3135213d8f36e92b78
bb9bdc0b3349e4284e09149f943790b4
8033ca42935069373af5ab4e353035cb
b86025954724ab095521c863299222a7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio del Instituto Nacional de Enfermedades Neoplásicas
repository.mail.fl_str_mv repositorio@inen.sld.pe
_version_ 1868438568274231296
spelling PublicationRioja, PatriciaRey-Cardenas, MDe Velasco, Guillermo2025-09-30T08:29:10Z2025-09-30T08:29:10Z2025https://doi.org/10.1016/j.ctrv.2024.102801https://hdl.handle.net/20.500.14703/475Cancer Treatment ReviewsRenal cell carcinoma (RCC) is a heterogenous disease which the incidence is increasing worldwide. The identification and understanding of the role of the Von Hipple Lindau (VHP) in regulating the hypoxia-inducible factor signaling pathway has revolutionized the treatment of this disease. Belzutifan is an oral hypoxiainducible factor (HIF)-2α inhibitor, which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease and for the treatment of adults with RCC who experienced disease progression after PD-1/PD-L1– and VEGFR-targeted therapies. One of the most common adverse effect of this drug is anemia; however, it is treatment is not well known. This review summarizes role of the VHL-HIF pathway in ccRCC aroused the interest of targeting HIF activity, the history of belzutifan development and their relationship to anemia as well as propose a management algorithmapplication/pdfengElsevierUKinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/anemiacell carcinomahttps://purl.org/pe-repo/ocde/ford#3.02.30Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinomainfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENORIGINAL1-s2.0-S0305737224001294-main.pdf1-s2.0-S0305737224001294-main.pdfapplication/pdf3448037https://repositorio.inen.sld.pe/backend/api/core/bitstreams/5ccdd6de-0ac5-436b-bfdd-1257dc78e484/download6c94a0f53e92fb3135213d8f36e92b78MD51trueAnonymousREADLICENSElicense.txtWritten by org.dspace.content.LicenseUtilstext/plain; charset=utf-81748https://repositorio.inen.sld.pe/backend/api/core/bitstreams/9c6dad5a-e942-40c2-ab83-21c4a9e0be42/downloadbb9bdc0b3349e4284e09149f943790b4MD52falseAnonymousREADTEXT1-s2.0-S0305737224001294-main.pdf.txtWritten by FormatFilter org.dspace.app.mediafilter.TikaTextExtractionFilter on 2025-10-01T08:01:34Z (GMT).Extracted texttext/plain54617https://repositorio.inen.sld.pe/backend/api/core/bitstreams/b6e2e749-1a7d-4f0f-8fee-e9a907a5d2d3/download8033ca42935069373af5ab4e353035cbMD53falseAnonymousREADTHUMBNAIL1-s2.0-S0305737224001294-main.pdf.jpgWritten by FormatFilter org.dspace.app.mediafilter.PDFBoxThumbnail on 2025-10-01T08:01:35Z (GMT).Generated Thumbnailimage/jpeg42499https://repositorio.inen.sld.pe/backend/api/core/bitstreams/e87620ff-8001-40c1-ae48-7d63485a84be/downloadb86025954724ab095521c863299222a7MD54falseAnonymousREAD20.500.14703/475oai:repositorio.inen.sld.pe:20.500.14703/4752026-02-17T14:16:14.537Zhttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessopen.accesshttps://repositorio.inen.sld.peRepositorio del Instituto Nacional de Enfermedades Neoplásicasrepositorio@inen.sld.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
score 12.821158
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares